Um Soyoun, Ha Jueun, Choi Soo Jin, Oh Wonil, Jin Hye Jin
Research Team for Immune Cell Therapy, Biomedical Research Institute, MEDIPOST Co., Ltd., Seongnam 13494, South Korea.
Research Team for Osteoarthritis, Biomedical Research Institute, MEDIPOST Co., Ltd., Seongnam 13494, South Korea.
World J Stem Cells. 2020 Dec 26;12(12):1511-1528. doi: 10.4252/wjsc.v12.i12.1511.
Umbilical cord blood (UCB) is a primitive and abundant source of mesenchymal stem cells (MSCs). UCB-derived MSCs have a broad and efficient therapeutic capacity to treat various diseases and disorders. Despite the high latent self-renewal and differentiation capacity of these cells, the safety, efficacy, and yield of MSCs expanded for clinical applications remains a concern. However, immunomodulatory effects have emerged in various disease models, exhibiting specific mechanisms of action, such as cell migration and homing, angiogenesis, anti-apoptosis, proliferation, anti-cancer, anti-fibrosis, anti-inflammation and tissue regeneration. Herein, we review the current literature pertaining to the UCB-derived MSC application as potential treatment strategies, and discuss the concerns regarding the safety and mass production issues in future applications.
脐带血（UCB）是间充质干细胞（MSCs）的原始且丰富的来源。源自脐带血的间充质干细胞具有广泛且高效的治疗能力，可用于治疗各种疾病和病症。尽管这些细胞具有较高的潜在自我更新和分化能力，但用于临床应用的间充质干细胞的安全性、有效性和产量仍是令人担忧的问题。然而，在各种疾病模型中已出现免疫调节作用，表现出特定的作用机制，如细胞迁移与归巢、血管生成、抗凋亡、增殖、抗癌、抗纤维化、抗炎和组织再生。在此，我们综述了有关将源自脐带血的间充质干细胞应用作为潜在治疗策略的当前文献，并讨论了未来应用中有关安全性和大规模生产问题的担忧。
